Each sterile vial is sealed to maintain stability
Voices are calling for caution, as severe cases can even lead to death
No other option beats this for covered patients
During an open public hearing before the vote, the panel heard from multiple speakers, including public health advocates, physicians, and peptide companies, who expressed widely differing views on whether BPC-157 should be included on the 503A bulk drug list
A RANDOMISED clinical trial has found that low-dose semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, reduces alcohol craving and some measures of alcohol consumption in adults with alcohol use disorder (AUD), supporting the need for larger trials to explore its potential as a treatment
10.1111/j.1742-4658.2008.06800.x 29 Grether-BeckS.MariniA.JaenickeT.KrutmannJ